Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis - An Indian experience

Journal of Association of Physicians of India

Volumn 56, Issue JUNE, 2008, Pages 418-424

  Sethi, B K ^a   Chadha, M ^b   Modi, K D ^c   Prasanna Kumar, K M ^d   Mehrotra, R ^e   Sriram, Usha ^f  

^a CARE HOSPITAL   (India)

^b P D HINDUJA NATIONAL HOSPITAL   (India)

^c Medwin Hospital   (India)

^d M S RAMAIAH MEDICAL COLLEGE   (India)

^e APOLLO HOSPITALS   (India)

^f APOLLO HOSPITALS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT; CALCIUM; PARATHYROID HORMONE[1-34]; VITAMIN D;

AGED; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; MIDDLE AGED; MULTICENTER STUDY; OSTEOLYSIS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; TERIPARATIDE; TREATMENT OUTCOME; VITAMIN D;

EID: 44649084990     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 2000;11:551-2.
2. Shatrugna V, Kulkarni B, Kumar AP, Rani KU, Balakrishna N. Bone status of Indian women from a low-income group and its relationship to the nutritional status. Osteoporosis Int 2005;16:1827-35.
3. Black DM, Cummings SR, Karpf DB, Cauley CJ, Thompson DE, Nevitt MC, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
4. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999; 282:637-45.
5. Rosen CJ, Bilezikian JP. Anabolic therapy for osteoporosis. J Clin Endocrinology Metab 2001;86:957-64.
6. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703.
7. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
8. Shah RS, Savardekar L, Iddya U, Balaiah D, Parithar A, Jhankaria B. First Indian study on bone density measurement in Indian women - salient outcomes. Osteoporosis Alert 2004;1:3.
9. Mithal A, Nangia S, Arya V, Verma BR, Gujral RB. Spinal bone mineral density in normal Indian females (Abstract). J Bone Miner Res 1998;13 (Suppl:1):S591.
10. Gupta A. Osteoporosis in India - the nutritional hypothesis. Natl Med J India 1996;9:268-74.
11. Harinarayan CV, Ramalakshmi T, Venkataprasad U. High prevalence of low dietary calcium and low vitamin D status in healthy south Indians. Asia Pacific J Clin Nutr 2004;13:359-65.
12. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, et al. Efficacy and safety of human parathyroid hormone (1-84) in increasing BMD in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88:5212-20.
13. Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164:2024-30.
14. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:4528-35.
15. World Medical Association declaration of helsinki - clarification of General Assembly : ethical principles for medical research involving human subjects. (Accessed December 8, 2007, available from http://www.wma.net/e/ policy/b3.htm).
16. Ellenberg SS. Scientific and ethical issues in the use of placebo and active controls in clinical trials. J Bone Miner Res 2003;18:1121-4.
17. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327:1637-42.
18. Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response of teriparatide is largely independent of age, initial bone mineral density and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:18-23.
19. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 1998;102:1627-33.
20. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006; 21:1785-90.
21. De Gruttola VG, Clax P, DeMets DL, Ellenberg SS, Friedman L, Gail MH, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health workshop. Control Clin Trials 2001; 22:485-502.
22. U.S. Department of Health and Human Services. Bone health and osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon Genreral, 2004.
23. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-24.
24. McClung M, Geusens P, Miller P, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40.
25. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39.